News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Swedish Orphan Biovitrum to Refinance Existing Credit Facility

6/5/2012 9:15:58 AM

STOCKHOLM, SWEDEN--(Marketwire - June 05, 2012) - Sobi has decided to refinance its existing credit facility either by issuing a SEK denominated bond up to SEK 500 M or by entering into a new revolving credit facility with SEB and Nordea.

The purpose of the refinancing is to improve the financial flexibility and to extend the maturity profile. The refinancing will replace existing bank debt and will not increase Sobi's total debt.

Sobi has appointed Nordea as Joint Bookrunner and Co-ordinator together with SEB as Joint Bookrunner to investigate a bond issue. The lead banks Nordea and SEB have committed to provide a credit facility in a corresponding amount in the event that Sobi does not proceed with the bond issue.

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 5 June 2012 at 16.50 CET.

Sobi Press Release on June 5 in pdf format:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE


For further information, please contact:
Lars Sandstrom
Tel.: +46 8 697 26 33

Read at

comments powered by Disqus